Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 02, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine...
June 01, 2026 16:40 ET | Source: University of Miami

University of Miami Miller School of Medicine Names Dr. Pradeep Ramulu Chair of Ophthalmology and the Bascom Palmer Eye Institute

Miami, Florida, June 01, 2026 (GLOBE NEWSWIRE) -- The University of Miami Miller School of Medicine announced the appointment of Pradeep Y. Ramulu, M.D., M.H.S., Ph.D., as chair of the Department of...
June 01, 2026 08:46 ET | Source: Outlook Therapeutics, Inc.

Outlook Therapeutics Announces Resubmission of Biologics License Application to U.S. FDA for ONS-5010/LYTENAVA™ (bevacizumab-vikg)

ISELIN, N.J., June 01, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™...
June 01, 2026 01:00 ET | Source: F. Hoffmann-La Roche Ltd

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with...
June 01, 2026 00:59 ET | Source: NVIDIA

NVIDIA, Foxconn and Taiwan Medical Centers Bring Agentic and Physical AI to ‘Healthy Taiwan’

News Summary: Foxconn is deploying NVIDIA AI across Taiwan’s leading medical centers, transitioning from using individual AI tools to coordinated AI agent workforces that help clinicians reason,...
May 29, 2026 15:06 ET | Source: Oculis Holding AG

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial...
May 29, 2026 14:52 ET | Source: Oculis Holding AG

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema

ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The...
May 28, 2026 11:36 ET | Source: Spherix Global Insights

Brepocitinib Interest Gains Momentum in Idiopathic Inflammatory Myopathies as Rheumatologists Signal Readiness for Targeted, Steroid-Sparing Therapies

Exton, PA, May 28, 2026 (GLOBE NEWSWIRE) -- Spherix Global Insights has released the 2026 update of Market Dynamix™: Idiopathic Inflammatory Myopathies (IIM), US, revealing a market increasingly...
May 27, 2026 11:16 ET | Source: Research and Markets

U.S. Medical Coding Market Size, Share, Trends Analysis and Growth Forecasts Report 2026-2033

Dublin, May 27, 2026 (GLOBE NEWSWIRE) -- The "U.S. Medical Coding Market Size, Share & Trends Analysis Report by Classification System, Component, Medical Specialty, End Use, and Growth...
May 27, 2026 10:40 ET | Source: Spherix Global Insights

Eli Lilly’s Oral GLP-1 Foundayo Trails Novo Nordisk’s Wegovy Pill in Early Obesity Launch Uptake, According to Spherix Global Insights

Exton, PA, May 27, 2026 (GLOBE NEWSWIRE) -- As the obesity treatment landscape rapidly evolves, newly launched oral GLP-1 based treatments are introducing alternate treatment options for patients...